Announcement PDF 2024 Full Year Results Webinar 28 Feb 2025 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Pa g e□1 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 Large potential upside for shareholders is enabled by financial strength Maximise value of NNZ-2591 as a multiple indication platform  Positive Phase 2 results for Phelan-McDermid syndrome  Positive Phase 2 results for Angelman syndrome Value  Positive Phase 2 results for Pitt Hopkins syndrome Long-term income growth from Acadia’s successful global commercialization of A$359 million pro-forma cash1 1 A$222 million cash and short-term investments at 31 December 2024, adjusted to include receipt in Q1 2025 of PRV sale proceeds, sales milestone and Q4 2024 royalty and payment in Q1 2025 of Q4 2024 tax 3 The 2024 numbers – a record year of income for shareholders Comprehensive income (CI) CI margin A$166m 73% Total comprehensive income (A$m) 157.1 NPAT FX gain A$142m A$24m Corporate & admin costs R&D investment in NNZ-2591 A$5m A$33m DAYBUE revenue 23 & 24 Pro-forma cash 0.2 A$445m A$359m 2022 2023 166.2 2024 4 Record high cash reserve organically generated to fund growth Cash and Pro-forma Cash (A$m) 80.5 18.7 -38.5 76.5 359.4 222.2 Cash at 31 Dec 24 PRV Sales milestone Q4 24 royalty Q4 24 tax paid Q1 25* Pro-forma cash * Includes US withholding tax on Q4 24 royalty and sales milestone payment 5 Growing sustainable income for Neuren from DAYBUE in US DAYBUE US Net Sales (US$m) + 9-16% + 97% 348 405 + 11-19% 380 + 110% 177 CY2023 (Apr Dec) US Royalty to Neuren (A$m) 56 67 62 27 CY2024 CY2025 Acadia Guidance CY2023 CY2024 CY2025E* * Based on CY25 Acadia DAYBUE US Net Sales Guidance of US$380-405m, 10% of DAYBUE net sales up to US$250m and 12% of DAYBUE net sales between US$250m and US$500m, and AUDUSD of 0.65 6 Q4 2024 was a record quarter of DAYBUE sales since launch in the US US Net Sales (US$m) CY23 DAYBUE US$177m 87 67 Significant further growth potential in the US1: CY24 DAYBUE US$350m (up 97% y-o-y) 76 85 91 • 97 • • 23 • Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 DAYBUE US Comparable Drug Launch (US)^ Diagnosed population expanding towards prevalence of 6,000-9,000 Currently 5,500–5,800 diagnosed patients in the US, grown from 4,500 at launch Continue growing new patient starts beyond 30% of diagnosed patients treated to date • Acadia increasing size of field force by ~30% and use of predictive analytics • Launching branded direct-to-consumer campaigns • Bringing positive experience to life, using growing body of real-world evidence, including LOTUS study, HCP peer-to-peer program, caregiver program series Maintaining stabilized persistency rate • 50% or higher after 12 months • 62% of active patients have been on treatment >12 months ^ For illustrative purposes only. Comparable Orphan Drug has different patient/clinician experience, approval and distribution/logistical dynamics 1. Latest stats based on Acadia 4Q and full year 2024 Earnings Presentation 26 February 2025 and 43rd Annual JP Morgan Healthcare Conference Presentation 14 January 2025 7 Long term growth opportunity for trofinetide through global expansion Canada 600 - 900 Rett patients1 Approved in Oct 2024 First sales in Q3 2025 US 6,000 - 9,000 Rett patients1 Launched in Apr 2023 Europe 9,000 - 12,000 Rett patients1 MAA filed with potential approval Q1 2026 Initiation of Managed Access Program Q2 2025 Acadia building EU leadership and launch teams Japan 1,000 - 2,000 Rett patients1 PMDA discussions ongoing; clinical study start by Q3 2025 to support marketing application 1 Acadia estimates 8 Economics to Neuren from Acadia partnership North America  US$10m Outside North America  US$100m upfront in 2018 upfront in 2023  US$10m in 2022 following acceptance of NDA for review US$35m following 1st commercial sale in Europe US$40m in 2023 following 1st commercial sale in the US US$15m following 1st commercial sale in Japan US$50m In 2024 one third share of Priority Review Voucher awarded to Acadia (sold for US$150m) US$10m following 1st commercial sale of a 2nd indication Europe US$55m Milestone payments related to Fragile X US$4m following 1st commercial sale of a 2nd indication Japan   Tiered Royalty Rates (% of net sales) Sales Milestones Annual Net Sales Rates Net Sales in one calendar year ≤US$250m 10% ≥US$250m  50 >US$250m, ≤US$500m 12% ≥US$500m 50 >US$500m, ≤US$750m 14% ≥US$750m 100 >US$750m 15% ≥US$1bn 150 US$m Sales milestones On achievement of escalating annual net sales thresholds: Europe: up to US$170m Japan: up to US$110m RoW: up to US$83m Tiered royalties Mid-teens to low-20s % of net sales 9 Leveraging trofinetide experience into multiple indications for NNZ-2591 Most advanced clinical program in PMS and PTHS, oral therapy competitive in AS Indications NNZ-2591 Phelan-McDermid syndrome (PMS) Orphan Rare Pediatric Fast Track Positive Phase 2 Positive EoP2 Meeting Commence Phase 3 Plan for mid year 2025; type C meeting in April 2025 Pitt Hopkins syndrome (PTHS) Angelman syndrome (AS) Other pending 10 Key milestones met and targeted Milestones Achieved in 2024 2025 Milestones  CY2024 DAYBUE net sales of ~US$348m in the US, generated A$56m royalties to Neuren and exceeded threshold for first sales milestone of US$50m  Submission by Acadia of EU marketing application for trofinetide • First sales by Acadia of DAYBUE in Canada (Q3 2025)  CY2024 Neuren total comprehensive income of A$166m • Initiation by Acadia of Managed Access Program for trofinetide in Europe (Q2 2025)  DAYBUE approved by Health Canada • CY2025 DAYBUE US net sales guidance US$380 – 405m, implying US$62 – 67m US royalties to Neuren2 • Confirm alignment with FDA on primary efficacy assessment for PMS Phase 3 trial at Type C meeting in April  Positive Phase 2 results for PMS, PTHS, AS • Commence Phase 3 trial for PMS  Positive End of Phase 2 meeting with FDA for PMS •  A$222m cash at 31 Dec 2024, A$359m pro-forma cash1 Advance PTHS and AS to registration trials subject to FDA consultation • Advance Prader-Willi syndrome and/or undisclosed indications  Trofinetide PIP accepted by EMA  PRV sold for US$150m, Neuren received 1/3 1 A$222 million cash and short-term investments at 31 December 2024, adjusted to include receipt in Q1 2025 of PRV sale proceeds, sales milestone and Q4 2024 royalty and payment in Q1 2025 of Q4 2024 tax 2 Based on CY25 Acadia DAYBUE Net Sales Guidance of US$380-405m, 10% of DAYBUE net sales up to US$250m and 12% of DAYBUE net sales between US$250m and US$500m, and AUDUSD of 0.65 11 CONTACT investorrelations@neurenpharma.com Authorised by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 12